NEWS HIGHLIGHTSMedia Articles Related to Amitiza (Lubiprostone)
Health Tip: Help Control Constipation (HealthDay)
Source: Y! Health Digestive Health News [2009.11.12]
HealthDay - (HealthDay News) -- Constipation occurs when it becomes
difficult or painful to have regular bowel movements. What's "regular"
varies by person, however.
Health Tip: Help Control Constipation
Source: MedicineNet Constipation Specialty [2009.11.12]
Title: Health Tip: Help Control Constipation
Category: Health News
Created: 11/12/2009 8:10:00 AM
Last Editorial Review: 11/12/2009
Ironwood And Forest Announce Positive Linaclotide Results From Two Pivotal Phase 3 Trials In Patients With Chronic Constipation
Source: Irritable-Bowel Syndrome News From Medical News Today [2009.11.04]
Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from two Phase 3 clinical trials assessing the safety and efficacy of once-daily dosing of the investigational drug linaclotide in patients with chronic constipation (CC).
Health Tip: Help Prevent Your Child's Constipation
Source: MedicineNet Constipation Specialty [2009.09.25]
Title: Health Tip: Help Prevent Your Child's Constipation
Category: Health News
Created: 9/25/2009 8:10:00 AM
Last Editorial Review: 9/25/2009
Health Tip: When Constipation Requires a Doctor's Appointment
Source: MedicineNet Laxatives For Constipation Specialty [2009.08.03]
Title: Health Tip: When Constipation Requires a Doctor's Appointment
Category: Health News
Created: 8/1/2009 7:00:00 AM
Last Editorial Review: 8/3/2009
Published Studies Related to Amitiza (Lubiprostone)
Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. [2009.02.01]
BACKGROUND: Effective treatments for irritable bowel syndrome with constipation (IBS-C) are lacking. AIM: To assess the efficacy and safety of lubiprostone in IBS-C... CONCLUSIONS: The percentage of overall responders based on patient-rated assessments of IBS-C symptoms was significantly improved in patients treated with lubiprostone 8 mcg twice daily compared to those treated with placebo. Lubiprostone was well tolerated with a favourable safety profile.
Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. [2009.02]
Lubiprostone, a bicyclic fatty acid chloride channel activator, is efficacious in treatment of chronic constipation and constipation-predominant irritable bowel syndrome. The study aim was to compare effects of lubiprostone and placebo on colonic sensory and motor functions in humans...
Single-dose lubiprostone along with split-dose PEG solution without dietary restrictions for bowel cleansing prior to colonoscopy: a randomized, double-blind, placebo-controlled trial. [2008.09]
OBJECTIVES: Proper colonic cleansing prior to colonoscopy is paramount to ensuring complete mucosal visualization and polyp identification. In a double-blind fashion, we compared single-dose lubiprostone (24 microg) versus placebo pretreatment prior to a split-dose polyethylene glycol electrolyte (PEG-E) bowel preparation without dietary restriction to determine the efficacy, safety, and patient tolerability... CONCLUSIONS: Single-dose lubiprostone prior to split-dose PEG-E without dietary restriction significantly improves colonic mucosa visualization during colonoscopy and is well tolerated by patients.
Single-Dose Lubiprostone Along With Split-Dose PEG Solution Without Dietary Restrictions for Bowel Cleansing Prior to Colonoscopy: A Randomized, Double-Blind, Placebo-Controlled Trial. [2008.08.05]
OBJECTIVES: Proper colonic cleansing prior to colonoscopy is paramount to ensuring complete mucosal visualization and polyp identification. In a double-blind fashion, we compared single-dose lubiprostone (24 mug) versus placebo pretreatment prior to a split-dose polyethylene glycol electrolyte (PEG-E) bowel preparation without dietary restriction to determine the efficacy, safety, and patient tolerability... CONCLUSIONS: Single-dose lubiprostone prior to split-dose PEG-E without dietary restriction significantly improves colonic mucosa visualization during colonoscopy and is well tolerated by patients.
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. [2008.04]
BACKGROUND: Analyses of a trial in constipated patients indicated that lubiprostone may be an effective treatment for irritable bowel syndrome with constipation. AIM: To assess the efficacy and safety of three lubiprostone doses for irritable bowel syndrome with constipation... CONCLUSION: Lubiprostone significantly improved gastrointestinal symptoms of irritable bowel syndrome with constipation at all doses. Higher doses of lubiprostone, especially the 48 microg/day group, were associated with more gastrointestinal adverse events. From these data, the 16 microg/day dose demonstrated the optimal combination of efficacy and safety. These results warrant further study of lubiprostone for treatment of irritable bowel syndrome with constipation patients.
Clinical Trials Related to Amitiza (Lubiprostone)
Amitiza® Plus GoLYTELY® Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation [Recruiting]
The primary objective is to compare the effectiveness and tolerance of Amitiza®
(lubiprostone) plus GoLYTELY® (polyethylene glycol-electrolyte solution) versus placebo and
GoLYTELY ® (polyethylene glycol-electrolyte solution) as a bowel cleansing preparation for
colonoscopy.
Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-Induced Constipation After Surgery in Inpatient Rehabilitation [Recruiting]
Patients requiring opioids for post-operative pain control following elective orthopedic
procedures which has resulted in constipation symptoms, and who are in inpatient
rehabilitation will be randomized to two different treatment arms: lubiprostone or senna.
Baseline scores regarding constipation and a quality of life bowel questionnaire will be
compared the day following 6 days of treatment intervention.
Amitiza in Constipation Associated With PD (Parkinson's Disease) [Recruiting]
The purpose of this study is to determine if Amitiza (lubiprostone), a drug proven to be
safe and effective for chronic constipation, will also improve constipation symptoms in
Parkinson's Disease patients. We will also evaluate the impact of the drug on changes in
bowel movement consistency, quality of life and motor symptoms.
Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation [Recruiting]
The primary purpose of this study is to evaluate the safety and efficacy of lubiprostone in a
pediatric population with constipation, including the pharmacokinetics of lubiprostone, in a
subset of patients.
Lubiprostone as a Treatment for Constipation in Parkinson's Disease [Recruiting]
Delayed colonic transient time secondary to a multi-degenerative process is the most likely
cause of constipation in idiopathic PD. Since lubiprostone demonstrated its ability to
accelerate colonic transit time in healthy volunteers in addition to activating the chloride
channels in the intestinal cells, it has the potential to improve constipation in patients
with PD with no subsequent adverse events on the control of the neurological manifestation
of PD. So we hypothesize the following:
1. Lubiprostone will improve ratings on the Bristol stool form scale (BSFS) in patients
with PD induced constipation compared to baseline.(primary)
2. Lubiprostone will increase the number of spontaneous bowel movements (SBM) per week,
compared to baseline. (secondary)
3. Lubiprostone will improve health related quality of life in subjects with PD induced
constipation. ( secondary)
|
